Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

13 mars 2019 uppdaterad av: National Cancer Institute (NCI)

Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer

This phase II trial studies how well giving bevacizumab, radiation therapy, and combination chemotherapy works in treating patients who are undergoing surgery for locally advanced nonmetastatic rectal cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as capecitabine, may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with radiation therapy and combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving bevacizumab together with combination chemotherapy after surgery may kill any tumor cells that remain after surgery.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

PRIMARY OBJECTIVES:

I. To evaluate the pathological complete response rate in patients with T3 and T4 rectal cancers when treated preoperatively with capecitabine, oxaliplatin, bevacizumab, and concurrent radiotherapy (XRT).

II. To evaluate the resection rate for T3 and T4 rectal cancers and the expected versus actual type of resection (abdominoperinal resection [APR] vs. low anterior resection [LAR] vs. LAR/coloanal anastomosis).

III. To make preliminary observations of patient survival and patterns of recurrence for this treatment combination.

IV. To gain additional experience regarding the toxicity and tolerability of this preoperative and postoperative regimen.

OUTLINE:

PREOPERATIVE CHEMORADIOTHERAPY: Patients undergo radiotherapy (total dose to the tumor bed was 5040 cGy) once daily (QD) 5 days a week and receive capecitabine 825 mg/m^2 orally (PO) twice daily (BID) 5 days a week for 5.5 weeks. Patients also receive oxaliplatin 50 mg/m^2 intravenously (IV) over 2 hours on days 1, 8, 15, 22, and 29 and bevacizumab 5 mg/kg IV over 30-90 minutes on days 1, 15, and 29 during radiotherapy.

SURGERY: Approximately 6-8 weeks after completion of chemoradiotherapy, patients undergo surgical resection. Patients whose tumors are not completely resected or who have metastatic disease discontinue protocol therapy.

POSTOPERATIVE CHEMOTHERAPY: Approximately 4-12 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium 400 mg/m^2 IV over 2 hours, and bevacizumab 5 mg/kg IV over 30-90 minutes on day 1. Patients also receive fluorouracil 2400 mg/m^2 IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 9 courses in the absence of disease progression or unacceptable toxicity. Patients then receive up to 3 additional courses of leucovorin calcium, fluorouracil, and bevacizumab.

After completion of study treatment, patients are followed up periodically for 10 years.

Studietyp

Interventionell

Inskrivning (Faktisk)

57

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35233
        • University of Alabama at Birmingham Cancer Center
    • Connecticut
      • New Britain, Connecticut, Förenta staterna, 06050
        • The Hospital of Central Connecticut
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Decatur, Georgia, Förenta staterna, 30033
        • Atlanta VA Medical Center
      • Macon, Georgia, Förenta staterna, 31201
        • Medical Center of Central Georgia
    • Illinois
      • Aurora, Illinois, Förenta staterna, 60504
        • Rush - Copley Medical Center
      • Berwyn, Illinois, Förenta staterna, 60402
        • MacNeal Hospital and Cancer Center
      • Chicago, Illinois, Förenta staterna, 60611
        • Northwestern University
      • Chicago, Illinois, Förenta staterna, 60625
        • Swedish Covenant Hospital
      • Chicago, Illinois, Förenta staterna, 60611
        • Hematology and Oncology Associates
      • Chicago, Illinois, Förenta staterna, 60657
        • Presence Saint Joseph Hospital-Chicago
      • Chicago, Illinois, Förenta staterna, 60612
        • Jesse Brown Veterans Affairs Medical Center
      • Chicago, Illinois, Förenta staterna, 60616
        • Mercy Hospital and Medical Center
      • Effingham, Illinois, Förenta staterna, 62401
        • Saint Anthony Memorial Hospital
      • Highland Park, Illinois, Förenta staterna, 60035
        • Hematology Oncology Associates of Illinois-Highland Park
      • Hinsdale, Illinois, Förenta staterna, 60521
        • Hinsdale Hematology Oncology Associates Incorporated
      • Joliet, Illinois, Förenta staterna, 60435
        • Joliet Oncology-Hematology Associates Limited
      • Joliet, Illinois, Förenta staterna, 60432
        • Midwest Center for Hematology Oncology
      • Libertyville, Illinois, Förenta staterna, 60048
        • NorthShore Hematology Oncology-Libertyville
      • Moline, Illinois, Förenta staterna, 61265
        • Garneau, Stewart C MD (UIA Investigator)
      • Moline, Illinois, Förenta staterna, 61265
        • Porubcin, Michael MD (UIA Investigator)
      • Moline, Illinois, Förenta staterna, 61265
        • Spector, David MD (UIA Investigator)
      • Moline, Illinois, Förenta staterna, 61265
        • Trinity Medical Center
      • Moline, Illinois, Förenta staterna, 61265
        • Sharis, Christine M MD (UIA Investigator)
      • Moline, Illinois, Förenta staterna, 61265
        • Stoffel, Thomas J MD (UIA Investigator)
      • Moline, Illinois, Förenta staterna, 61265
        • Vigliotti, Antonio, P.G. M.D. (UIA Investigator)
      • Naperville, Illinois, Förenta staterna, 60563
        • DuPage Medical Group-Ogden
      • Niles, Illinois, Förenta staterna, 60714
        • Illinois Cancer Specialists-Niles
      • Skokie, Illinois, Förenta staterna, 60076
        • Hematology Oncology Associates of Illinois - Skokie
      • Skokie, Illinois, Förenta staterna, 60076
        • Edward H Kaplan MD and Associates
      • Urbana, Illinois, Förenta staterna, 61801
        • Carle Cancer Center
    • Indiana
      • Michigan City, Indiana, Förenta staterna, 46360
        • Franciscan Saint Anthony Health-Michigan City
    • Iowa
      • Bettendorf, Iowa, Förenta staterna, 52722
        • Constantinou, Costas L MD (UIA Investigator)
      • Sioux City, Iowa, Förenta staterna, 51101
        • Siouxland Regional Cancer Center
      • Sioux City, Iowa, Förenta staterna, 51102
        • Mercy Medical Center-Sioux City
      • Sioux City, Iowa, Förenta staterna, 51104
        • Saint Luke's Regional Medical Center
    • Michigan
      • Kalamazoo, Michigan, Förenta staterna, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, Förenta staterna, 49007
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, Förenta staterna, 49048
        • Borgess Medical Center
    • Minnesota
      • Burnsville, Minnesota, Förenta staterna, 55337
        • Fairview Ridges Hospital
      • Coon Rapids, Minnesota, Förenta staterna, 55433
        • Mercy Hospital
      • Edina, Minnesota, Förenta staterna, 55435
        • Fairview-Southdale Hospital
      • Fridley, Minnesota, Förenta staterna, 55432
        • Unity Hospital
      • Hutchinson, Minnesota, Förenta staterna, 55350
        • Hutchinson Area Health Care
      • Litchfield, Minnesota, Förenta staterna, 55355
        • Meeker County Memorial Hospital
      • Maplewood, Minnesota, Förenta staterna, 55109
        • Saint John's Hospital - Healtheast
      • Maplewood, Minnesota, Förenta staterna, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, Förenta staterna, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Förenta staterna, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Förenta staterna, 55407
        • Virginia Piper Cancer Institute
      • Robbinsdale, Minnesota, Förenta staterna, 55422
        • North Memorial Medical Health Center
      • Saint Louis Park, Minnesota, Förenta staterna, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Louis Park, Minnesota, Förenta staterna, 55416
        • Metro Minnesota Community Oncology Research Consortium
      • Saint Paul, Minnesota, Förenta staterna, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Förenta staterna, 55102
        • United Hospital
      • Saint Paul, Minnesota, Förenta staterna, 55102
        • Saint Joseph's Hospital - Healtheast
      • Shakopee, Minnesota, Förenta staterna, 55379
        • Saint Francis Regional Medical Center
      • Waconia, Minnesota, Förenta staterna, 55387
        • Ridgeview Medical Center
      • Woodbury, Minnesota, Förenta staterna, 55125
        • Minnesota Oncology Hematology PA-Woodbury
      • Woodbury, Minnesota, Förenta staterna, 55125
        • Woodwinds Health Campus
    • Nebraska
      • Lincoln, Nebraska, Förenta staterna, 68510
        • Nebraska Cancer Research Center
      • Omaha, Nebraska, Förenta staterna, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, Förenta staterna, 68122
        • Alegent Health Immanuel Medical Center
      • Omaha, Nebraska, Förenta staterna, 68131
        • Creighton University Medical Center
      • Omaha, Nebraska, Förenta staterna, 68106
        • Missouri Valley Cancer Consortium
    • New Jersey
      • Mount Holly, New Jersey, Förenta staterna, 08060
        • Virtua Memorial
      • Sparta, New Jersey, Förenta staterna, 07871
        • Sparta Cancer Treatment Center
      • Voorhees, New Jersey, Förenta staterna, 08043
        • Virtua Voorhees
      • Woodbury, New Jersey, Förenta staterna, 08096
        • Inspira Medical Center Woodbury
    • New York
      • Bronx, New York, Förenta staterna, 10467
        • Montefiore Medical Center - Moses Campus
      • Bronx, New York, Förenta staterna, 10466
        • Montefiore Medical Center-Wakefield Campus
    • Ohio
      • Akron, Ohio, Förenta staterna, 44304
        • Summa Akron City Hospital/Cooper Cancer Center
      • Barberton, Ohio, Förenta staterna, 44203
        • Summa Barberton Hospital
      • Bellefontaine, Ohio, Förenta staterna, 43311
        • Mary Rutan Hospital
      • Chillicothe, Ohio, Förenta staterna, 45601
        • Adena Regional Medical Center
      • Columbus, Ohio, Förenta staterna, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Förenta staterna, 43228
        • Doctors Hospital
      • Columbus, Ohio, Förenta staterna, 43215
        • Grant Medical Center
      • Columbus, Ohio, Förenta staterna, 43222
        • Mount Carmel Health Center West
      • Delaware, Ohio, Förenta staterna, 43015
        • Grady Memorial Hospital
      • Lancaster, Ohio, Förenta staterna, 43130
        • Fairfield Medical Center
      • Lima, Ohio, Förenta staterna, 45801
        • Saint Rita's Medical Center
      • Marietta, Ohio, Förenta staterna, 45750
        • Marietta Memorial Hospital
      • Newark, Ohio, Förenta staterna, 43055
        • Licking Memorial Hospital
      • Springfield, Ohio, Förenta staterna, 45505
        • Springfield Regional Medical Center
      • Westerville, Ohio, Förenta staterna, 43081
        • Saint Ann's Hospital
      • Zanesville, Ohio, Förenta staterna, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Tulsa, Oklahoma, Förenta staterna, 74136
        • Natalie Warren Bryant Cancer Center at Saint Francis
    • Pennsylvania
      • Allentown, Pennsylvania, Förenta staterna, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Darby, Pennsylvania, Förenta staterna, 19023-1291
        • Mercy Fitzgerald Hospital
      • East Stroudsburg, Pennsylvania, Förenta staterna, 18301
        • Pocono Medical Center
      • Ephrata, Pennsylvania, Förenta staterna, 17522
        • Ephrata Cancer Center
      • Media, Pennsylvania, Förenta staterna, 19063
        • Riddle Memorial Hospital
      • Philadelphia, Pennsylvania, Förenta staterna, 19111
        • Fox Chase Cancer Center
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • Thomas Jefferson University Hospital
      • Philadelphia, Pennsylvania, Förenta staterna, 19141
        • Einstein Medical Center Philadelphia
      • Philadelphia, Pennsylvania, Förenta staterna, 19114
        • Aria Health-Torresdale Campus
      • Scranton, Pennsylvania, Förenta staterna, 18508
        • Hematology and Oncology Associates of North East Pennsylvania
      • Upland, Pennsylvania, Förenta staterna, 19013
        • Associates In Hematology Oncology PC-Upland
    • South Dakota
      • Sioux Falls, South Dakota, Förenta staterna, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, Förenta staterna, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, Förenta staterna, 57104
        • Sanford Cancer Center Oncology Clinic
      • Sioux Falls, South Dakota, Förenta staterna, 57105
        • Medical X-Ray Center
      • Sioux Falls, South Dakota, Förenta staterna, 57105
        • Avera McKennan Hospital and University Health Center
    • Texas
      • Dallas, Texas, Förenta staterna, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
    • Wisconsin
      • La Crosse, Wisconsin, Förenta staterna, 54601
        • Gundersen Lutheran Medical Center
      • Milwaukee, Wisconsin, Förenta staterna, 53226
        • Froedtert and The Medical College of Wisconsin

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients must have histologically confirmed, locally advanced, non-metastatic primary T3 or T4 adenocarcinoma of the rectum
  • Patients must not have evidence of tumor outside of the pelvis including liver metastases, peritoneal seeding, or metastatic inguinal lymphadenopathy
  • Patients must not have intra-operative radiotherapy (IORT) or brachytherapy treatment to the pelvis
  • The distal border of the tumor must be at or below the peritoneal reflection, defined as within 12 centimeters of the anal verge by proctoscopic examination
  • Transmural penetration of tumor through the muscularis propria must be demonstrated by either of the following: computed tomography (CT) scan plus endorectal ultrasound, or a magnetic resonance imaging (MRI); an endorectal coil or pelvic MRI is allowed
  • For the patient to be eligible, the surgeon must prospectively define the tumor as either initially resectable or potentially resectable after pre-operative chemoradiation; clinically resectable tumors are defined as completely resectable with negative margins based on routine examination of the non-anesthetized patient; patients whose tumors are not resectable are not eligible; before pre-operative (op) treatment, the surgeon should estimate and record the type of resection anticipated: pelvic exenteration, posterior pelvic exenteration, APR, LAR, or LAR/coloanal anastomosis

  • Patients with tumors that are clinically fixed, clinical stage T4N0-2, M0 are eligible if it is believed that their tumors are potentially resectable after chemoradiation; based on the following:

    • Clinically fixed tumors on rectal examination with tumor adherent to the pelvic sidewall or sacrum
    • Sciatica attributed to sacral root invasion with CT scan/MRI evidence of the lack of clear tissue plane will be considered evidence of fixation
    • Hydronephrosis on CT scan or intravenous pyelogram (IVP) or ureteric or bladder invasion as documented by cystoscopy and cytology or biopsy, or invasion into prostate
    • Vaginal or uterine involvement
  • Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • A surgical evaluation must confirm patient's ability to tolerate the proposed surgical procedure
  • Patients must have a caloric intake > 1500 kilocalories/day (d)
  • Within 4 weeks prior to registration, the patient's absolute neutrophil count (ANC) level must be >= 1,500/mm^3
  • Within 4 weeks prior to registration, the patients platelet level must be >= 100,000/mm^3
  • Within 4 weeks prior to registration, serum creatinine must be < 1.5 X upper limit of normal (ULN); if serum creatinine > 1.5 x ULN, then creatinine clearance must be >= 50 mL/mm
  • Within 4 weeks prior to registration, serum bilirubin must be =< 1.5 X ULN
  • Within 4 weeks prior to registration, alkaline phosphatase (alk phos) must be < 2 x ULN
  • Within 4 weeks prior to registration, serum glutamic oxaloacetic transaminase (SGOT) must be < 2 x ULN
  • Carcinoembryonic antigen (CEA) must be determined prior to initiation of therapy
  • Within 4 weeks prior to registration, urine protein/creatinine (UPC) ratio must be < 1; patients with a ratio of >= 1 must undergo a 24-hour urine collection which must be an adequate collection and must demonstrate < 1 gram (gm) of protein in order to participate
  • Within 4 weeks prior to registration, albumin must be >= 2 gm/dl
  • Absence of clinical evidence of high-grade (lumen diameter < 1 cm) large bowel obstruction, unless diverting colostomy has been performed
  • Eligible patients of reproductive potential (both sexes) must agree to use an accepted and effective method of contraceptive during study therapy and for at least 6 months after the completion of bevacizumab
  • Women must not be pregnant or breast-feeding; all females of childbearing potential must have a serum pregnancy test to rule out pregnancy within 2 weeks of registration
  • Patients must have had no prior chemotherapy for rectal cancer or pelvic irradiation therapy
  • Patients with prior malignancies, including pelvic cancer, are eligible if they have been disease free for > 5 years; patients with prior in situ carcinomas are eligible provided there was complete removal
  • Patients must have no active inflammatory bowel disease or other serious medical illness or disease that might limit the patient's ability to receive protocol therapy
  • Patients with a history of cerebrovascular accident (CVA)/transient ischemic attack (TIA) at any time, or myocardial infarction/unstable angina within 12 months of study entry are not eligible
  • Patients with > grade 1 peripheral neuropathy are not eligible
  • Patients must have urine protein/creatinine (UPC) ratio of < 1.0; patients with a UPC ratio >= 1.0 must undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate < 1 gm of protein in order to participate
  • Patients with a history of hypertension must measure < 150/90 mmHg and be on a stable regimen of anti-hypertensive therapy
  • Patients with clinically significant peripheral vascular disease are not eligible

  • Patients must not have any of the following:

    • Unstable angina (within 12 months of study entry)
    • New York Heart Association (NYHA) grade II or higher congestive heart failure
    • Evidence of bleeding diathesis/coagulopathy
    • Serious non-healing wound or bone fracture

  • Patients with a history of the following within 28 days prior to registration are not eligible:

    • Abdominal fistula
    • Gastrointestinal perforation
    • Intrabdominal abscess

  • Patients with a history of the following within 28 days prior to day 0 (first treatment day) are not eligible:

    • Major surgical procedure
    • Open biopsy
    • Significant traumatic injury
  • Patients must not have core biopsy within 7 days prior to day 0 (first treatment day)

  • Patients with prothrombin time (PT) (international normalized ratio [INR]) > 1.5 are not eligible, unless the patient is on full-dose anticoagulants; if so, the following criteria must be met for enrollment:

    • The subject must have an in-range INR (usually between 2 and 3), be on a stable dose of warfarin or on a stable dose of low molecular weight heparin
    • The subject must not have active bleeding or a pathological condition that is associated with a high risk of bleeding

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment (bevacizumab and chemoradiotherapy)
See Detailed Description
Biologisk: Bevacizumab
Givet IV
Andra namn:
  • Avastin
  • Anti-VEGF
  • Anti-VEGF humaniserad monoklonal antikropp
  • Anti-VEGF rhuMAb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar QL 1101
  • Immunoglobulin G1 (Människ-mus Monoklonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfid Med Human-Mus Monoklonal rhuMab-VEGF lätt kedja, Dimer
  • Rekombinant humaniserad anti-VEGF monoklonal antikropp
  • rhuMab-VEGF
  • BEVACIZUMAB, LICENSINNEHAVARE OSPECIFICERAD
Läkemedel: Fluorouracil
Givet IV
Andra namn:
  • 5-FU
  • 5-Fluracil
  • Fluracil
  • 5-fluor-2,4(lH,3H)-pyrimidindion
  • 5-Fluorouracil
  • AccuSite
  • Carac
  • Fluoro Uracil
  • Fluouracil
  • Flurablastin
  • Fluracedyl
  • Fluril
  • Fluroblastin
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757
Läkemedel: Oxaliplatin
Givet IV
Andra namn:
  • 1-OHP
  • Dakotin
  • Dacplat
  • Eloxatin
  • Ai Heng
  • Aiheng
  • Diaminocyklohexan Oxalatoplatina
  • JM-83
  • Oxalatoplatin
  • Oxalatoplatina
  • RP 54780
  • RP-54780
  • SR-96669
Läkemedel: Capecitabin
Givet PO
Andra namn:
  • Xeloda
  • Ro 09-1978/000
Läkemedel: Leucovorin Kalcium
Givet IV
Andra namn:
  • Wellcovorin
  • citrovorum faktor
  • folinsyra
  • Adinepar
  • Kalcifolin
  • Kalcium (6S)-folinat
  • Kalciumfolinat
  • Kalcium Leucovorin
  • Calfolex
  • Calinat
  • Cehafolin
  • Citofolin
  • Citrec
  • Cromatonbic Folinico
  • Dalisol
  • Disintox
  • Divical
  • Ecofol
  • Emovis
  • Faktor, Citrovorum
  • Flynoken A
  • Folaren
  • Folaxin
  • FOLI-cell
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Folinatkalcium
  • Folinsyra Kalciumsalt Pentahydrat
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leucosar
  • leukovorin
  • Rescufolin
  • Rescuvolin
  • Tonofolin
Procedur: Terapeutisk konventionell kirurgi
Genomgå kirurgisk resektion
Strålning: Strålterapi
Genomgå strålbehandling
Andra namn:
  • Cancer Strålbehandling
  • Bestråla
  • Bestrålat
  • Strålning
  • Radioterapeutika
  • RT
  • Terapi, strålning
  • bestrålning
  • RADIOTERAPI

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pathologic Complete Response Rate
Tidsram: Assessed at surgery time
Pathologic complete response to preoperative therapy was determined at the time of surgical resection. Pathologic complete response (pCR) is defined as no evidence of invasive cells on pathologic examination of the primary rectal cancer (or tissue from the area where the tumor had been if there is a complete clinical response). Pathologic complete response rate is calculated as number of patients achieving pathologic complete response divided by all eligible and treated patients
Assessed at surgery time

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Resection Rate for T3 Rectal Cancers
Tidsram: Assessed at surgery time
Resection rate is defined as number of patients with T3 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T3 rectal cancers
Assessed at surgery time
Resection Rate for T4 Rectal Cancers
Tidsram: Assessed at surgery time
Resection rate is defined as number of patients with T4 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T4 rectal cancers
Assessed at surgery time
5-year Overall Survival Rate
Tidsram: survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
Overall survival is defined as time from registration to death from any cause. 5-year overall survival rate is estimated using Kaplan-Meier method.
survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
5-year Recurrence-free Survival Rate
Tidsram: recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
Recurrence free survival is defined as time from surgery to disease recurrence or death without recurrence (whichever occurred first) among resected patients. 5-year recurrence-free survival rate is estimated using Kaplan-Meier method, with 90% confidence interval calculated using Greenwood's formula.
recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

National Cancer Institute (NCI)

Utredare

  • Huvudutredare: Jerome C Landry, ECOG-ACRIN Cancer Research Group

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

25 juli 2006

Primärt slutförande (Faktisk)

12 augusti 2013

Avslutad studie (Faktisk)

11 februari 2019

Studieregistreringsdatum

Först inskickad

2 maj 2006

Först inskickad som uppfyllde QC-kriterierna

2 maj 2006

Första postat (Uppskatta)

4 maj 2006

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

27 mars 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 mars 2019

Senast verifierad

1 mars 2019

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • NCI-2009-01081 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
  • U10CA180820 (U.S.S. NIH-anslag/kontrakt)
  • U10CA021115 (U.S.S. NIH-anslag/kontrakt)
  • CDR0000471148
  • ECOG-E3204
  • E3204 (Annan identifierare: CTEP)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Rektal Adenocarcinom

Kliniska prövningar på Bevacizumab

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Hungary

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera